Market
U.S. emergency use authorization for self-amplifying RNA COVID-19 vaccine by June 30, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from the U.S. Food and Drug Administration (FDA)
Story
EU to Approve U.S. Self-Amplifying RNA COVID-19 Vaccine Following Japan's Approval of ARCT-154 Self-Replicating mRNA
Dec 17, 2024, 02:23 PM
The European Union is set to approve a new self-amplifying RNA-based COVID-19 vaccine developed by a U.S. company. This follows Japan's recent approval of a similar self-replicating mRNA vaccine, ARCT-154, which allows the mRNA to replicate within cells. The advancements in mRNA technology, including the use of lipid nanoparticles (LNPs), are aimed at enhancing vaccine efficacy and targeting specific diseases. Researchers have also made progress in developing modified LNPs capable of crossing the blood-brain barrier, potentially enabling targeted therapies for brain and inflammatory diseases.
View original story
Similar markets
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
